Sector News

GSK, Pfizer and Johnson & Johnson race toward $10B-plus RSV vaccine market: analyst

September 12, 2021
Life sciences

While COVID-19 vaccines set all sorts of industry launch records, another potential megablockbuster vaccine market looms on the horizon. Some of pharma’s top players including Pfizer, Johnson & Johnson and GlaxoSmithKline are expected to be involved.

RSV, or respiratory syncytial virus, has long been a top target for vaccine developers. While companies have suffered high-profile trial failures over the years, vaccines are now advancing through late-stage testing and could launch in 2023, SVB Leerink analyst Geoffrey Porges wrote to clients this week.

As companies race to the FDA finish line, a market worth $10.5 billion could take shape over the next decade, Porges says.

Based on currently available information, the analyst expects vaccine giant GSK to nab $2.9 billion of that total revenue by 2030, while Pfizer collects $2.1 billion, J&J picks up $1.7 billion and Sanofi scores $1.2 billion.

GSK, Pfizer and GlaxoSmithKline are all in late-stage testing for their RSV shots. Sanofi, while it’s a leading vaccine player worldwide, is taking another approach with its late-stage RSV program. The company and partner AstraZeneca are working on a prophylactic monoclonal antibody for infants, and they plan to file for approval next year.

Other vaccine and drug developers including Bavarian Nordic and Moderna are in mid-stage testing or earlier in RSV and are expected to capture $2.6 billion of the overall market, Porges wrote.

As for the three leading vaccines from Pfizer, GSK and J&J, Porges expects “more or less equal timing” for their launches and a “low probability of real differentiation between the programs.” The analysts’ team plans to update their RSV sales model over time as more data become available.

Just last week, Pfizer started a phase 3 trial of its RSV vaccine candidate in adults 60 and older. With the company’s COVID-19 vaccine launch experience, the company could be a “significant” competitor in the field, Porges wrote. Pfizer expects results as early as the first quarter of 2022, Porges wrote.

GSK expects a late-stage readout for its trial in the second half of next year. J&J hasn’t released its expected phase 3 trial timeline.

By 2030, Porges expects that 72% of the RSV market will come from adults, while 10% comes from maternal immunization—or vaccinating mothers to protect their babies—and 18% comes from infants.

RSV, the top cause of pneumonia and pneumonia in children under one, is spread through respiratory droplets or contact with a contaminated surface. The virus usually emerges in the fall in the United States and peaks in the winter.

But in recent months amid the COVID-19 pandemic, experts have been noting an uptick in RSV cases. During an unusual summer RSV season, pediatric hospitals reported infections around the Southern United States, the CDC warned in June.

by Eric Sagonowsky

Source: fiercepharma.com

comments closed

Related News

September 12, 2021

Sanofi to buy Kadmon for $1.9B, extending deal streak

Life sciences

The deal, announced Wednesday, has Sanofi paying $9.50 per share in cash for Kadmon, a roughly 77% premium to the biotech’s Tuesday closing price and 113% more than its average trading price over the last two months.

September 12, 2021

Google, Mayo Clinic build new type of AI algorithm to map interactions between areas of the brain

Life sciences

By monitoring which areas of the brain responded to localized electrical stimulation, scientists from the Google Research Brain Team and Mayo Clinic developed an artificial intelligence algorithm to map out the structure of brain networks.

September 12, 2021

Theranos founder Elizabeth Holmes’ defense paints her as a ‘naive’ but ambitious CEO in fraud trial opening statement

Life sciences

As Elizabeth Holmes’ federal fraud trial began, in response to prosecutors’ claims that she knowingly defrauded investors, partners and patients in pursuit of fame and wealth, the former Theranos founder and CEO’s defense team described her as merely an inexperienced leader who made serious mistakes.

Send this to a friend